In Phase A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. Additional contributors will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Section https://abbv-744-clinical-trial-p46790.blog2freedom.com/32018182/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers